Phalguni Deswal
LightNews LightNews
phalguniddw.bsky.social
Phalguni Deswal
@phalguniddw.bsky.social
20 followers 11 following 230 posts
Editor - Drug and Device World
Posts Replies Media Videos
phalguniddw.bsky.social
Abbott’s $21B acquisition of Exact Sciences signals a new era in cancer detection. We analyze the high-stakes MCED market, pivotal FDA decisions, and the reimbursement battle ahead with Gabelli Funds’ Elena Meng.

#MCED #cancerscreening #Abbott #ExactSciences #healthcareinvesting #biotech
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott's $21 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Ming talks about the major players in the sector and hurdles.
druganddeviceworld.com
January 16, 2026 at 10:30 AM
phalguniddw.bsky.social
FDA approves Stereotaxis MAGiC robotic ablation catheter. A breakthrough for treating complex heart arrhythmias with precise magnetic navigation.
#News #Stereotaxis #FDAapproval #cardiology #robotics #arrhythmia #healthtech
Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation
The US FDA approves Stereotaxis' robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.
druganddeviceworld.com
January 15, 2026 at 10:42 AM
phalguniddw.bsky.social
Clinical trial start-up delays are rising due to complex protocols & contract bottlenecks. ICON survey data reveals 55% of sites take 5+ months to activate. Solutions require site-centricity & smarter tech.
#Interview #ClinicalTrials #StudyStartup #SiteCentricity #ICON #DrugDevelopment
Examining the growing delays in clinical trial start-up
ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
druganddeviceworld.com
January 15, 2026 at 10:09 AM
phalguniddw.bsky.social
EA Pharma (Eisai) starts Phase III trial in Japan for evenamide, a novel glutamate modulator for schizophrenia.
The drug was licensed as part of a €117M deal with Newron Pharmaceuticals.

#News #Schizophrenia #ClinicalTrial #MentalHealth #Biotech #Eisai #Evenamide
Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan
EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.
druganddeviceworld.com
January 10, 2026 at 3:05 PM
phalguniddw.bsky.social
Canopy secures $22M Series B to expand its connected safety platform for combating workplace violence and modernize hospital operations with location intelligence.
#News #HealthTech #SeriesB #WorkplaceSafety #Innovation #LocationIntelligence
Canopy raises $22 million for healthcare safety platform
The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.
druganddeviceworld.com
January 10, 2026 at 2:19 PM
phalguniddw.bsky.social
New #research by endogene.bio reveals why #endometriosis treatments often fail. The study identifies molecular subgroups & predicts drug response, suggesting non-invasive monitoring via menstrual blood could guide precision therapy.
#News #WomensHealth #PrecisionMedicine #ClinicalTrials
Endometriosis study uncovers molecular subgroups to guide trials
Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.
druganddeviceworld.com
January 7, 2026 at 5:53 PM
phalguniddw.bsky.social
Gallop’s LYT-200 shows 13.2-month median survival in late-line AML at #ASH2025—far exceeding historic benchmarks. The anti-galectin-9 antibody combines strong efficacy with a clean safety profile.

#News #Leukemia #Oncology #Biotech #ClinicalTrials #AML
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
druganddeviceworld.com
January 6, 2026 at 2:37 PM
phalguniddw.bsky.social
Healing chronic wounds twice as fast? SweetBio’s honey-based biomaterial is tackling the hidden amputation crisis, blending ancient remedies with cutting-edge science. #News #WoundCare #Diabetes #MedTech #Innovation #Biomaterials #DiabeticFootUlcer
SweetBio’s honey-based bandage saving limbs and closing wounds
The US-based company’s CEO talks about how novel biomaterial tackles the hidden crisis of chronic wounds, blending ancient remedies with modern science to prevent amputations.
druganddeviceworld.com
December 26, 2025 at 6:12 PM
phalguniddw.bsky.social
CNS Pharmaceuticals re-engineers old chemotherapies to cross the blood-brain barrier, targeting aggressive glioblastoma. Dr. Sandra Silberman explains their "back to the future" strategy and two promising drugs. #BrainCancer #Glioblastoma #Biotech #Oncology #BloodBrainBarrier #CNSPharmaceuticals
Old becomes New: CNS Pharma’s quest to tackle brain cancers
CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.
druganddeviceworld.com
December 24, 2025 at 11:37 AM
phalguniddw.bsky.social
New data at #ASH2025 show Secure Bio's Copiktra's (duvelisib) consistent efficacy in heavily pretreated PTCL, with strong signal in AITL informing Phase 3 TERZO trial in nTFHL.
#news #interview #lymphoma #clinicaltrials #oncology
Secura Bio’s Copiktra PTCL data shines at ASH 2025 
The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.
druganddeviceworld.com
December 23, 2025 at 10:32 AM
phalguniddw.bsky.social
FoRx Therapeutics raises $50M Series A to advance clinical trial of FORX-428, a PARG inhibitor for PARP-resistant cancers. Initial data expected mid-2026.
#News #Biotech #Funding #Oncology #ClinicalTrials #PARG
FoRx secures $50 million to advance PARG inhibitor
Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.
druganddeviceworld.com
December 18, 2025 at 9:23 PM
phalguniddw.bsky.social
CTMC’s global alliance partners with Brazil’s Einstein Hospital to democratize cell therapy. CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide.
#News #Interview #CellTherapy #GlobalHealth #MedicalInnovation
CTMC maps out plans to democratize cell therapy
CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide, starting with Brazil.
druganddeviceworld.com
December 17, 2025 at 10:04 AM
phalguniddw.bsky.social
FDA approves Cardamyst, the Milestone Pharmaceuticals’ self-administered nasal spray for PSVT. A rapid at-home treatment for sudden rapid heart episodes, available in 2026.
#News #PSVT #CARDAMYST #FDAapproval #HeartHealth #MedicalNews
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.
druganddeviceworld.com
December 16, 2025 at 7:26 PM
phalguniddw.bsky.social
Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds, aiming to prevent amputations. Read more for company's pipeline and future plans
#MedTech #WoundCare #FDA #Diabetes #Innovation #Interview #News
Rapid Nexus charts a new path for chronic wounds
Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds and the company’s pipeline.
druganddeviceworld.com
December 15, 2025 at 8:55 AM
phalguniddw.bsky.social
New data from Agendia's FLEX study at #SABCS2025 shows genomic signatures like MammaPrint can guide chemo choices & identify benefit in elderly patients.
#news #breastcancer #precisionmedicine #realworldevidence
SABCS25: Agendia’s genomic testing guides breast cancer care 
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.
druganddeviceworld.com
December 12, 2025 at 8:09 PM
phalguniddw.bsky.social
HeartBeam receives FDA clearance for the first cable-free, at-home 12-lead ECG. This breakthrough allows for clinical-grade heart rhythm assessment anytime, anywhere. A major leap for remote cardiac care.
#New #HeartBeam #FDA #MedTech #Cardiology #DigitalHealth
HeartBeam’s stock shows strong pulse after FDA clearance
A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.
druganddeviceworld.com
December 12, 2025 at 7:29 PM
phalguniddw.bsky.social
AC Immune's Phase 2 vaccine for Parkinson’s shows first-ever signs of potentially slowing disease progression. 100% 100% responder rate for immunogenicity & stabilized biomarkers signal a promising step forward.
#News #Parkinsons #Biotech #ClinicalTrial #Neurodegenerative #ACI7104
AC Immune’s stock rises with positive Phase II data
Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson's treatment.
druganddeviceworld.com
December 12, 2025 at 7:06 PM
phalguniddw.bsky.social
VUGENE teams up with CRO Inotiv to accelerate AI-driven drug discovery through advanced multi-omics analysis. A key move into the pharmaceutical services market.

#News #AI #DrugDiscovery #MultiOmics #Bioinformatics #CRO #Biotech
VUGENE partners with Inotiv to power AI-driven drug discovery
Lithuanian bioinformatics firm launches into pharmaceutical services via a strategic CRO collaboration aimed at accelerating multi-omics analysis.
druganddeviceworld.com
December 12, 2025 at 6:22 PM
phalguniddw.bsky.social
Sanofi’s #ASH25 data highlight leadership in rare blood diseases, from multi-immune modulation with #BTKinhibitor Wayrilz to long-term hemophilia care with ALTUVIIIO. Transforming patient lives through science.
#News #Interview #RareDisease #Hemophilia #Immunoscience
Sanofi’s ASH 2025: Redefining rare blood disorder care
Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.
druganddeviceworld.com
December 10, 2025 at 11:57 AM
phalguniddw.bsky.social
Vyome shares rise on positive Phase 2 data for its wound care gel VT-1953, showing significant reduction in odor & pain. Pivotal study targeted for 2026.
#News #Biotech #ClinicalTrial #Healthcare #WoundCare
Vyome’s stock rises on positive Phase II data for wound care drug
Vyome's VT-1953 gel significantly reduced odor and pain in malignant fungating wounds, prompting plans for a pivotal Phase III study.
druganddeviceworld.com
December 9, 2025 at 11:19 AM
phalguniddw.bsky.social
Tessera Therapeutics' Gene Writing platform hits new preclinical milestones. Data shows edited stem cells exceed curative thresholds for sickle cell disease & successful in vivo generation of functional CAR-T cells.
#News #GeneWriting #SickleCellDisease #CAR_T #ASH2025 #Biotech
ASH25: Tessera’s gene writing hits curative thresholds in sickle cell
New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.
druganddeviceworld.com
December 9, 2025 at 10:17 AM
phalguniddw.bsky.social
BREAKING: Dicot Pharma unveils how LIB-01, a new class of ED drug, works. It targets the brain's melanocortin system for a sustained effect, even in non-responders. Phase 2a data shows benefits last 8+ weeks.

#News #EDtreatment #menshealth #clinicaltrial #ErectileDysfunction
Dicot Pharma unlocks sustained ED effect with LIB-01
Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.
druganddeviceworld.com
December 8, 2025 at 7:41 PM
phalguniddw.bsky.social
New data reveals ATIVA's RECELL spray-on skin treatment reduces burn patient hospital stays by 5.6 days, saving ~$42k per case. The minimally invasive approach means less pain, faster healing, and better cosmetic outcomes.
#BurnCare #News #MedicalInnovation #PatientOutcomes #HealthcareEfficiency
AVITA’s spray on skin cells slashes pain and hospital stays
Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.
druganddeviceworld.com
December 8, 2025 at 9:35 AM
phalguniddw.bsky.social
Iolyx Therapeutics partners with Laboratoires Théa in a deal worth up to $280M to advance ILYX-002, a novel eye drop for autoimmune dry eye. Phase 2 data showed early, sustained improvement.
#news #biotech #ophthalmology #dryeye #autoimmune #collaboration
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
druganddeviceworld.com
December 5, 2025 at 11:10 AM
phalguniddw.bsky.social
Shocked by the lack of funding in women's health, BioMed X launches XFem Labs with Gates Foundation to bridge the R&D gap. Their first mission: non-hormonal contraception.
#News #WomensHealth #HealthEquity #Biotech #GatesFoundation #Innovation
The $1 trillion blind spot: Bridging the gap in women’s health
Dr. Christian Tidona, founder and CEO of BioMed X, on why women's health is critically underfunded and how a new initiative aims to change that.
druganddeviceworld.com
December 5, 2025 at 10:37 AM